RCUS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

RC

Mkt Cap

$2.91B

Volume

1.18M

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% RunJuan C. Jaen, president of Arcus Biosciences, sold 68,569 shares for $2.0 million through a trust under a Rule 10b5-1 trading plan, while maintaining ~1.2 million shares. The sale appears motivated by tax and liquidity management following a 200% stock surge. Arcus has refocused on casdatifan, its HIF-2α kidney cancer drug, after discontinuing a lung cancer program, with pivotal Phase 3 readouts expected by year-end.The Motley Fool · Jul 13, 2026

Biotech Advances Drive Cancer Research as Global Rates Continue Upward TrendThe article discusses the global surge in cancer cases, particularly among people under 50, and the efforts of biotech companies to develop new therapies to combat this trend. It highlights recent progress and upcoming studies from several companies in the oncology space.Benzinga · Dec 2, 2024

Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.GlobeNewswire Inc. · Aug 23, 2024

Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences - Arcus Biosciences (NYSE:RCUS) - BenzingaArcus Biosciences (RCUS) underwent analysis by 4 analysts in the last quarter, with a downward trend in their 12-month price targets. The article provides a detailed breakdown of the analysts' recent evaluations, ratings, and price targets for the company.Benzinga · Jul 8, 2024

Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.Zacks Investment Research · Jun 7, 2024

Gilead (GILD), RCUS Announce Data From Colorectal Cancer StudyGilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.Zacks Investment Research · Jun 3, 2024

Wall Street Breakfast: The Week AheadThis article discusses upcoming market events and earnings reports, including the CoinDesk Consensus event and the release of the personal income and...Seeking Alpha · May 26, 2024

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue EstimatesArcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 8, 2024

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · May 2, 2024

Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should KnowArcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · May 1, 2024

RC

RCUSArcus Biosciences, Inc.

RCUS

Pay with—

Available Balance0.00

Your PositionYou don't own any RCUS yet.

Related Tickers

Earnings